drugset / Trial / NCT00520741

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

NCT00520741

Phase 3 Completed 426 enrolled UCB BIOSCIENCES, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.

Timeline

Start
2007-08
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lacosamide Other / unclassified 300 mg
Comparator Lacosamide Other / unclassified 400 mg

Indications